Literature DB >> 23601909

Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.

Leonardo Mastropasqua1, Luca Agnifili, Vincenzo Fasanella, Claudia Curcio, Cristina Ciabattoni, Rodolfo Mastropasqua, Lisa Toto, Marco Ciancaglini.   

Abstract

PURPOSE: To evaluate the density of conjunctival goblet cells (GCs) in glaucomatous patients treated with preservative-free (PF) tafluprost, using laser scanning confocal microscopy (LSCM) and impression cytology (IC).
METHODS: Thirty glaucomatous patients (30 eyes) naive for therapy and thirty healthy subjects (30 eyes) were enrolled. Conjunctiva was examined by means of Heidelberg Retina Tomography/Rostock cornea module. Afterwards, the specimens for IC were obtained. Patients were randomized to PF-tafluprost (Group 1) or preserved latanoprost (Group 2) and controls to the vehicle of latanoprost (Group 3) or physiological buffered saline solution (Group 4). Both LSCM and IC were performed at baseline, and after the 1st and 6th months of therapy, GC density (GCD) (cells/mm(2) ) was the main outcome measurement.
RESULTS: Baseline. Mean GCD was 240.69 ± 25.43 and 232.65 ± 23.52, for LSCM, and 162.10 ± 23.44 and 164.71 ± 21.03 for IC in Group 1 and 2, respectively. GC density values were not significantly different in Group 3 and 4 (p > 0.05%). Month one. Mean GCD increased to 284.16 ± 43.88 and 230.62 ± 48.32 in Group 1 (p < 0.001) and to 297.86 ± 26.87 and 221.78 ± 43.02 in Group 2 (p < 0.05), measured with LSCM and IC, respectively. In Group 3, GCD decreased to 205.88 ± 25.04 and 139.54 ± 17.37 measured with LSCM and IC, respectively (p < 0.05). Month six. Mean GCD did not change in Group 1 (p > 0.05) whereas it decreased in Group 2 (p < 0.05), compared to month 1. In Group 3, GCD further decreased to 166.32 ± 22.31 and 120.76 ± 11.66, measured with LSCM and IC, respectively (p < 0.05); in Group 4, mean GCD did not change during the study period (p > 0.05).
CONCLUSIONS: Treatment with PF tafluprost was associated with an increase in conjunctival GCD in glaucomatous eyes naïve for therapy. Further studies are mandatory to verify this finding because its validation may have important consequences in the medical management of glaucoma.
© 2013 Acta Ophthalmologica Scandinavica Foundation. Published by Blackwell Publishing Ltd.

Entities:  

Keywords:  conjunctival goblet cells; impression cytology and primary open angle glaucoma; in vivo confocal microscopy; preservative-free tafluprost

Mesh:

Substances:

Year:  2013        PMID: 23601909     DOI: 10.1111/aos.12131

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  18 in total

1.  Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.

Authors:  Manu Saini; Murugesan Vanathi; Tanuj Dada; Tushar Agarwal; Rebika Dhiman; Sudarshan Khokhar
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

2.  Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.

Authors:  Kai Kaarniranta; Kirsi Ikäheimo; Eliisa Mannermaa; Auli Ropo
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

3.  Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications.

Authors:  M Saini; R Dhiman; T Dada; R Tandon; M Vanathi
Journal:  Eye (Lond)       Date:  2015-04-10       Impact factor: 3.775

Review 4.  Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines.

Authors:  Laura García-Posadas; Laura Contreras-Ruiz; Laura Soriano-Romaní; Darlene A Dartt; Yolanda Diebold
Journal:  Eye Contact Lens       Date:  2016-03       Impact factor: 2.018

5.  Benzalkonium Chloride-Preserved Anti-Glaucomatous Eye Drops and Their Effect on Human Conjunctival Goblet Cells in vitro.

Authors:  Anne Hedengran; Xenia Begun; Olivia Müllertz; Zaynab Mouhammad; Rupali Vohra; Jeffrey Bair; Darlene A Dartt; Barbara Cvenkel; Steffen Heegaard; Goran Petrovski; Miriam Kolko
Journal:  Biomed Hub       Date:  2021-08-13

6.  In Vivo Scanning Laser Confocal Microscopy of Conjunctival Goblet Cells in Medically-controlled Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Marco Ciancaglini; Gianluca Murano; Enrico Borrelli; Leonardo Mastropasqua
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

Review 7.  In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Sara Cecannecchia; Angela DI Gregorio; Marco Ciancaglini
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

8.  A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.

Authors:  Paolo Fogagnolo; Angelica Dipinto; Elisa Vanzulli; Emanuele Maggiolo; Stefano De Cilla'; Alessandro Autelitano; Luca Rossetti
Journal:  Adv Ther       Date:  2015-04-19       Impact factor: 3.845

9.  Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study.

Authors:  Wenqing Zhu; Xiangmei Kong; Jianjiang Xu; Xinghuai Sun
Journal:  J Ophthalmol       Date:  2015-06-15       Impact factor: 1.909

Review 10.  Confocal Microscopy and Anterior Segment Optical Coherence Tomography Imaging of the Ocular Surface and Bleb Morphology in Medically and Surgically Treated Glaucoma Patients: A Review.

Authors:  Carmela Carnevale; Ivano Riva; Gloria Roberti; Manuele Michelessi; Lucia Tanga; Alice C Verticchio Vercellin; Luca Agnifili; Gianluca Manni; Alon Harris; Luciano Quaranta; Francesco Oddone
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.